{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-057461","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.787293+00:00","generated_at":"2026-06-15T09:17:00.271463+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Voyager Therapeutics appoints George Scangos to Board of Directors","bullets":["George Scangos, Ph.D., appointed as Class I director effective May 9, 2023, serving until 2025 annual meeting.","Scangos will serve on the Science and Technology Committee of the Board.","Compensation includes $40,000 annual cash retainer and initial option for 44,000 shares vesting over 4 years.","Scangos brings experience as former CEO of Biogen, Vir Biotechnology, and Exelixis.","He will enter standard indemnification agreement with Voyager."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-057461","json":"https://secwatch.observer/filing/0001104659-23-057461.json","markdown":"https://secwatch.observer/filing/0001104659-23-057461.md","text":"https://secwatch.observer/filing/0001104659-23-057461.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923057461/0001104659-23-057461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923057461/tm2314979d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:17:00.271463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"989e0cd2ea","claim":"George Scangos was appointed as director at Voyager Therapeutics, Inc..","evidence_excerpt":"On May 6, 2023, the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed George Scangos, Ph.D. as a director of the Company and as a member of the Science and Technology Committee of the Board, effective May 9, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923057461/0001104659-23-057461-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}